Peptinov Publishes Positive Phase 1 Results for PPV-06 in Nature Communications
PR Newswire —
PARIS, Dec. 18, 2025 /PRNewswire/ -- Peptinov today announced the publication of the Phase 1 clinical results for PPV-06, its first-in-class active immunotherapy targeting IL-6, in the peer-reviewed journal Nature Communications. The randomized, double-blind, placebo-controlled study was...